A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of
KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who
have not previously received systemic cytotoxic chemotherapy.